Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dimethylhydrazine | multiple interactions | ISO | Saraf (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of SARAF mRNA | CTD | PMID:22206623 | 17alpha-ethynylestradiol | increases expression | EXP | | 6480464 | Ethinyl Estradiol results in increased expression of SARAF mRNA | CTD | PMID:17557909 | 17beta-estradiol | multiple interactions | ISO | SARAF (Homo sapiens) | 6480464 | [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SARAF mRNA | CTD | PMID:20823114 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Saraf (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of SARAF mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of SARAF mRNA | CTD | PMID:33387578 and PMID:34747641 | 2,4-dinitrotoluene | affects expression | EXP | | 6480464 | 2 and 4-dinitrotoluene affects the expression of SARAF mRNA | CTD | PMID:21346803 | 4,4'-sulfonyldiphenol | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of SARAF mRNA | CTD | PMID:36041667 | acetamide | decreases expression | EXP | | 6480464 | acetamide results in decreased expression of SARAF mRNA | CTD | PMID:31881176 | acrylamide | increases expression | ISO | SARAF (Homo sapiens) | 6480464 | Acrylamide results in increased expression of SARAF mRNA | CTD | PMID:32763439 | ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of SARAF mRNA | CTD | PMID:16483693 | amphetamine | increases expression | EXP | | 6480464 | Amphetamine results in increased expression of SARAF mRNA | CTD | PMID:30779732 | antirheumatic drug | decreases expression | ISO | SARAF (Homo sapiens) | 6480464 | Antirheumatic Agents results in decreased expression of SARAF mRNA | CTD | PMID:24449571 | Aroclor 1254 | decreases expression | ISO | Saraf (Mus musculus) | 6480464 | Chlorodiphenyl (54% Chlorine) results in decreased expression of SARAF mRNA | CTD | PMID:23650126 | benzene | decreases expression | ISO | SARAF (Homo sapiens) | 6480464 | Benzene results in decreased expression of SARAF mRNA | CTD | PMID:15929907 | benzene | affects expression | EXP | | 6480464 | Benzene affects the expression of SARAF mRNA | CTD | PMID:15878777 | benzo[a]pyrene | increases expression | ISO | Saraf (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of SARAF mRNA | CTD | PMID:15034205 and PMID:22228805 | benzo[a]pyrene | multiple interactions | ISO | Saraf (Mus musculus) | 6480464 | AHR protein inhibits the reaction [Benzo(a)pyrene results in increased expression of SARAF mRNA] | CTD | PMID:15034205 | bisphenol A | increases expression | ISO | SARAF (Homo sapiens) | 6480464 | bisphenol A results in increased expression of SARAF mRNA | CTD | PMID:25047013 | bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of SARAF mRNA | CTD | PMID:36041667 | bisphenol A | increases expression | ISO | Saraf (Mus musculus) | 6480464 | bisphenol A results in increased expression of SARAF mRNA | CTD | PMID:33221593 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of SARAF mRNA | CTD | PMID:30816183 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of SARAF mRNA | CTD | PMID:25181051 | bisphenol F | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of SARAF mRNA | CTD | PMID:36041667 | bucladesine | multiple interactions | ISO | SARAF (Homo sapiens) | 6480464 | [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SARAF mRNA | CTD | PMID:20823114 | cadmium dichloride | decreases methylation | EXP | | 6480464 | Cadmium Chloride results in decreased methylation of SARAF promoter | CTD | PMID:22457795 | cadmium dichloride | increases expression | EXP | | 6480464 | Cadmium Chloride results in increased expression of SARAF mRNA | CTD | PMID:33453195 | celecoxib | affects expression | ISO | Saraf (Mus musculus) | 6480464 | Celecoxib affects the expression of SARAF mRNA | CTD | PMID:20562220 | chloropicrin | affects expression | ISO | SARAF (Homo sapiens) | 6480464 | chloropicrin affects the expression of SARAF mRNA | CTD | PMID:26352163 | clobetasol | increases expression | ISO | Saraf (Mus musculus) | 6480464 | Clobetasol results in increased expression of SARAF mRNA | CTD | PMID:27462272 | clofibrate | decreases expression | ISO | Saraf (Mus musculus) | 6480464 | Clofibrate results in decreased expression of SARAF mRNA | CTD | PMID:17585979 | cobalt dichloride | increases expression | ISO | SARAF (Homo sapiens) | 6480464 | cobaltous chloride results in increased expression of SARAF mRNA | CTD | PMID:19376846 | copper(II) sulfate | decreases expression | ISO | SARAF (Homo sapiens) | 6480464 | Copper Sulfate results in decreased expression of SARAF mRNA | CTD | PMID:19549813 | coumarin | increases expression | EXP | | 6480464 | coumarin results in increased expression of SARAF mRNA | CTD | PMID:18480146 | cyclosporin A | increases expression | ISO | SARAF (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of SARAF mRNA | CTD | PMID:20106945 | cytarabine | decreases expression | ISO | SARAF (Homo sapiens) | 6480464 | Cytarabine results in decreased expression of SARAF mRNA | CTD | PMID:21198554 | dibutyl phthalate | increases expression | EXP | | 6480464 | Dibutyl Phthalate results in increased expression of SARAF mRNA | CTD | PMID:21266533 | diuron | decreases expression | EXP | | 6480464 | Diuron results in decreased expression of SARAF mRNA | CTD | PMID:21551480 | diuron | decreases expression | ISO | SARAF (Homo sapiens) | 6480464 | Diuron results in decreased expression of SARAF mRNA | CTD | PMID:35967413 | doxorubicin | increases expression | ISO | SARAF (Homo sapiens) | 6480464 | Doxorubicin results in increased expression of SARAF mRNA | CTD | PMID:29803840 | endosulfan | increases expression | EXP | | 6480464 | Endosulfan results in increased expression of SARAF mRNA | CTD | PMID:29391264 | ethanol | affects splicing | ISO | Saraf (Mus musculus) | 6480464 | Ethanol affects the splicing of SARAF mRNA | CTD | PMID:30319688 | fenthion | decreases expression | ISO | Saraf (Mus musculus) | 6480464 | Fenthion results in decreased expression of SARAF mRNA | CTD | PMID:34813904 | flavonoids | decreases expression | EXP | | 6480464 | Flavonoids results in decreased expression of SARAF mRNA | CTD | PMID:18035473 | folic acid | multiple interactions | ISO | Saraf (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of SARAF mRNA | CTD | PMID:22206623 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of SARAF mRNA | CTD | PMID:33387578 | glafenine | increases expression | EXP | | 6480464 | Glafenine results in increased expression of SARAF mRNA | CTD | PMID:24136188 | hydralazine | multiple interactions | ISO | SARAF (Homo sapiens) | 6480464 | [Hydralazine co-treated with Valproic Acid] results in increased expression of SARAF mRNA | CTD | PMID:17183730 | inulin | multiple interactions | ISO | Saraf (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of SARAF mRNA | CTD | PMID:36331819 | lead(0) | affects expression | ISO | SARAF (Homo sapiens) | 6480464 | Lead affects the expression of SARAF mRNA | CTD | PMID:28903495 | levonorgestrel | multiple interactions | ISO | SARAF (Homo sapiens) | 6480464 | [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SARAF mRNA | CTD | PMID:19074003 | medroxyprogesterone acetate | multiple interactions | ISO | SARAF (Homo sapiens) | 6480464 | [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SARAF mRNA | CTD | PMID:20823114 | methylparaben | increases expression | ISO | SARAF (Homo sapiens) | 6480464 | methylparaben results in increased expression of SARAF mRNA | CTD | PMID:31745603 | nimesulide | increases expression | EXP | | 6480464 | nimesulide results in increased expression of SARAF mRNA | CTD | PMID:24136188 | paracetamol | increases expression | ISO | SARAF (Homo sapiens) | 6480464 | Acetaminophen results in increased expression of SARAF mRNA | CTD | PMID:22230336 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of SARAF mRNA | CTD | PMID:33387578 | paracetamol | affects expression | ISO | Saraf (Mus musculus) | 6480464 | Acetaminophen affects the expression of SARAF mRNA | CTD | PMID:17562736 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Saraf (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of SARAF mRNA | CTD | PMID:36331819 | propiconazole | increases expression | ISO | Saraf (Mus musculus) | 6480464 | propiconazole results in increased expression of SARAF mRNA | CTD | PMID:21278054 | sodium arsenite | decreases expression | ISO | SARAF (Homo sapiens) | 6480464 | sodium arsenite results in decreased expression of SARAF mRNA | CTD | PMID:28595984 and PMID:34032870 | sodium fluoride | increases expression | ISO | Saraf (Mus musculus) | 6480464 | Sodium Fluoride results in increased expression of SARAF protein | CTD | PMID:28918527 | tert-butyl hydroperoxide | decreases expression | ISO | Saraf (Mus musculus) | 6480464 | tert-Butylhydroperoxide results in decreased expression of SARAF mRNA | CTD | PMID:15003993 | testosterone undecanoate | multiple interactions | ISO | SARAF (Homo sapiens) | 6480464 | [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SARAF mRNA | CTD | PMID:19074003 | tetrachloromethane | affects expression | ISO | Saraf (Mus musculus) | 6480464 | Carbon Tetrachloride affects the expression of SARAF mRNA | CTD | PMID:17484886 | tetrachloromethane | increases expression | ISO | Saraf (Mus musculus) | 6480464 | Carbon Tetrachloride results in increased expression of SARAF mRNA | CTD | PMID:31919559 | tetrachloromethane | increases expression | EXP | | 6480464 | Carbon Tetrachloride results in increased expression of SARAF mRNA | CTD | PMID:30723492 | thapsigargin | increases expression | EXP | | 6480464 | Thapsigargin results in increased expression of SARAF protein | CTD | PMID:35544339 | trichloroethene | increases expression | EXP | | 6480464 | Trichloroethylene results in increased expression of SARAF mRNA | CTD | PMID:33387578 | urethane | increases expression | ISO | SARAF (Homo sapiens) | 6480464 | Urethane results in increased expression of SARAF mRNA | CTD | PMID:28818685 | valproic acid | multiple interactions | ISO | SARAF (Homo sapiens) | 6480464 | [Hydralazine co-treated with Valproic Acid] results in increased expression of SARAF mRNA | CTD | PMID:17183730 | valproic acid | increases expression | ISO | Saraf (Mus musculus) | 6480464 | Valproic Acid results in increased expression of SARAF mRNA | CTD | PMID:20546886 | |